Full Brain Solution is reportedly the only artificial intelligence (AI)-enabled software that facilitates detection of medium vessel occlusions (MeVOs) as well as anterior and posterior large vessel occlusions (LVOs) on computed tomography (CT) exams.
Ischemic strokes reportedly account for 87 percent of the 795,000 annual strokes that occur in the United States, according to the Centers for Disease Control and Prevention (CDC). Researchers have estimated that medium vessel occlusions (MeVOs) cause between 25 to 40 percent of ischemic strokes and 24 to 46 percent of ischemic strokes are due to large vessel occlusions (LVOs).
With these statistics in mind, Aidoc has launched the Full Brain Solution, an AI-powered software that helps diagnose MeVOs and LVOs on computed tomography (CT) scans.
"AI has shown remarkable success in enhancing workflow for patients with anterior LVOs, nearly halving the time to treatment. However, this is just the beginning. With Aidoc’s Full Brain Solution, we can now broaden these advancements to benefit a significantly larger patient population, leading to improved care and ultimately better outcomes,” noted Brian Mason, M.D., an associate professor of neuroendovascular surgery at the University of Illinois Champaign.
Aidoc has launched the Full Brain Solution, an AI-powered software that helps diagnose medium vessel occlusions (MeVOs) andlarge vessel occlusions (LVOs) on computed tomography (CT) scans. (Images courtesy of Aidoc.)
In addition to aiding the diagnosis of acute ischemic strokes, Aidoc said the Full Brain Solution utilizes AI image-based detection and natural language processing to enhance diagnosis and facilitate subsequent care for patients with brain aneurysms as well as subdural and intracerebral hemorrhages.
(Editor’s note: For related content, see "RapidAI Gets FDA Nod for AI Assessment of Non-Contrast CT for Acute Stroke Triage” and “FDA Clears AI-Powered Stroke Imaging Tool for Non-Contrast CT.”)
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Expanded FDA Approval Allows Use of Pluvicto Prior to Chemotherapy in Patients with mCRPC
March 28th 2025Recent research demonstrated a 59 percent reduced risk of progression or death with the radioligand therapy Pluvicto in comparison to a change of androgen receptor pathway inhibitor (ARPI) for patients with metastatic castration-resistant prostate cancer (mCRPC).
GE HealthCare Launches PET MPI Agent Flyrcado at ACC Conference
March 28th 2025The positron emission tomography myocardial perfusion imaging (PET MPI) agent, which offers a significantly higher half-life than other cardiac PET agents, was recently granted pass-through payment status by CMS that will go into effect on April 1, 2025.